DE SCR100

Proclaims May 2022 as "Cystic Fibrosis Awareness Month" in Delaware

Notes that cystic fibrosis affects approximately 35,000 children and adults in the United States and over 70,000 worldwide, with about 1,000 new cases diagnosed annually

Highlights that median survival age for cystic fibrosis patients has increased to 36 years due to advancements in research and medical treatments, compared to few children surviving to elementary school in the 1950s

References FDA approvals of lumacaftor/ivacaftor (2018) for children ages 2-5 and Trikafta (2019), a first triple combination therapy for the most common cystic fibrosis mutation

Directs that a copy of the resolution be presented to the Cystic Fibrosis Foundation